COVID-19 trials registries data warehouse

https://www.thaiclinicaltrials.org/show/TCTR20211102004

Karjbundid Surasit

offkarj1@hotmail.com

2021-11-02

Recruiting

RCT

Randomized

Parallel

Open label

single-center

Treatment

1. COVID-19 patients with age more than 15 year 2. Diagnosed as severe or critical COVID-19 infection 3. Already received favipirair or remdesivir in combination with corticosteroid (more than 6 mg of dexamethasone or equivalent dose) for more than 24-48 hours 4. Hyperinflammatory state including CRP &gt, 75 mg/L , ferritin &gt, 300 ng/ml and serum IL-6 level &gt, 20 pg/ml 5. Hypoxemia with PaO2 / FiO2 &lt, 300 and/or oxygen saturation room air &lt, 92 percent and/or Lung infiltration increasing more than 50 percent within 24-48 hours

1. Patients in terminal states (estimated no more than 24 hours alive) 2. Pregnancy 3. History of HA-330 catridge or Tocilizumab allergy 4. Recent myocardial infarction within 1 month 5. Persistent shock more than 12 hours 6. Patients who accepted DNR (do not resuscitation)

2

N/A

15

100

Thailand

Severe/critical disease at enrollment

7: Severe/critical disease at enrollment

24

mortality 28 day 28 day mortality

Phase 2

[{"arm_notes": "", "treatment_id": 566, "treatment_name": "Hemoperfusion", "treatment_type": "Non-pharmocologic agent", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]